Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. senior Avg
|
New words:
AAOM, accredited, accrual, Adage, alleviation, Amylin, antigen, APA, appetite, apportionment, arbitrage, aryl, attached, BCMA, bespoke, biotech, boost, browning, calcium, calming, cardiovascular, chimeric, chosen, CIS, CNS, compelling, consummated, Counsel, CSF, cytotoxicity, daily, DBS, deducted, deduction, Derecognition, Description, display, dopamine, DPF, drawdown, druggable, effectuated, element, EPO, erythropoietin, fashion, fat, fate, ft, gap, GIP, glucagon, glucose, guaranty, gut, hematocrit, hGH, hormone, HPRA, HRPA, HTA, hydrocarbon, IDA, immense, Immunology, improperly, insulinotropic, inventory, invoiced, invoicing, ionizing, IRA, IRP, Jannsen, job, killing, knock, leaving, lymphoma, machinery, main, margin, maximize, messenger, MIA, Morino, mouse, mRNA, muscle, NIST, nonfinancial, nuclease, oncology, opportunistically, outflow, outpace, outset, parathyroid, peptide, pill, polypeptide, PPQ, preparatory, profound, proliferation, proven, PTH, PYY, quantitative, ready, reconciling, repayable, repeatable, repeatedly, rescued, rescuing, residual, resistance, resistant, retraining, ROFN, Sanofi, Simplification, sq, SSP, Stargardt, stimulation, subscribe, template, threat, title, top, transplanted, truthful, tumor, tuning, ultra, undermine, underway, unregulated, upward, vacant, Vice, webinar, withheld, withholding, YY
Removed:
AGTC, Axovant, Biden, bill, billion, chairman, CJEU, closed, conduction, Conference, Consortium, CPRA, Czechia, Deletion, demonstrating, depth, destroyed, diverge, epidemic, EURETINA, founder, golden, gradually, headcount, holdback, infrared, Jumpstart, led, leukemia, Moreno, murine, nighttime, nonbinding, outbreak, parachute, Park, processed, renamed, rendered, resilient, revealed, River, rotation, scheduled, Shield, Society, stay, steering, supervisory, surgeon, Switzerland, Taxpayer, triplicate, tunnel, turned, vaccine, Virtual, vote, young
Financial report summary
?Competition
Biogen • Applied Genetic Technologies • Ocugen • uniQure • Spark Therapeutics • Sio Gene Therapies • Voyager Therapeutics • 4D Molecular Therapeutics • Mustang Bio • Nightstar TherapeuticsManagement Discussion
- License revenue was $14.0 million for the year ended December 31, 2023, compared to $15.9 million for the year ended December 31, 2022. This decrease is a result of the Company recognizing the deferred revenue progress of the $100.0 million upfront payment and the $30.0 million milestone payment received in connection with the Collaboration Agreement through the termination date of the Collaboration Agreement on December 20, 2023.
- General and administrative expenses were $47.3 million for the year ended December 31, 2023, compared to $46.6 million for the year ended December 31, 2022. The increase of $0.7 million was primarily due to an increase of $4.1 million in legal and accounting fees, $2.2 million in payroll and payroll-related costs, $0.4 million in share-based compensation and $0.1 million in rent and facilities costs. These increases were partially offset by a decrease of $4.2 million in other general and administrative costs, $1.3 million in insurance, $0.3 million in consulting fees and $0.3 million in depreciation.
- Clinical program expenses represent the direct costs for each clinical trial plus the cost of the clinical trial material charged from the manufacturing costs.